Renal tumors and second primary pancreatic tumors: a relationship with clinical impact?

Abstract

BackgroundThe occurrence of synchronous or metachronous renal cell carcinoma and pancreatic tumors has been described only in a few cases in the scientific literature. The study of double primary cancers is important because it might provide understanding of a shared genetic basis of different solid tumors and to detect patients at risk for secondary malignancy.MethodsIn a combined analysis of patient registries from University Departments of Urology and Visceral Surgery, 1178 patients with pancreatic tumors and 518 patients with renal cell carcinoma treated between 2001 and 2008 were evaluated,ResultsOverall 16 patients with renal cancer and synchronous (n = 6) or metachronous (n = 10) primary pancreatic tumors were detected. The median survival of all patients was 12.6 months, for the patients with synchronous resections 25.7 months and for the patients with metachronous resections 12.2 months, respectively.ConclusionsThe association between these two etiologies of malignancy demands more detailed epidemiological and molecular investigation. Clinical outcomes would support a resection as a recommended clinically valid option.

Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only

“…In addition, the most common locations of associated double primary tumors in the present study were found in the stomach (21.5%), colorectum (20.7%), lung (14.9%), and thyroid (10.7%). Conversely, the most common locations of associated double primary tumors in previous reports include stomach (n=51), thyroid (n=35), lung (n=22), and colorectum (n=20) ( S6 Table ) [ 8 , 12 , 14 - 17 , 20 ].…”

“…Gerdes and colleagues reported 13 double primary cancers among 69 pancreatic cancer cases (18.8%), and they observed no differences in clinical parameters including OS differences between patients with pancreatic cancer only and pancreatic cancer patients with additional primary tumors [ 9 ]. Previously, Muller et al [ 14 ] evaluated 16 synchronous or metachronous renal cell carcinomas and pancreatic cancers and they observed no survival difference between 1,178 pancreatic cancer only patients and 16 pancreatic cancer with renal cell carcinoma (median survival time, 15.9 months vs. 12.6 months). In the present study, we observed only three pancreatic cancer cases with synchronous or metachronous renal cell carcinomas, and no OS difference was observed between pancreatic cancer patients with renal cell carcinoma and those with pancreatic cancer only.…”

“…For example, Tagawa et al [ 12 ] reported seven nonsmall cell lung cancers in patients with a history of pancreatic cancers, and the estimated 5-year survival rate was 68.6%, which was better than the survival rate of patients with pancreatic cancer only. Additionally, Muller et al [ 14 ] reported 16 primary pancreatic cancers among patients with renal cell carcinomas. All 16 cases had renal cell carcinomas that were diagnosed first or synchronously with pancreatic cancers, and the estimated 5-year survival rate was 23.1% [ 14 ].…”

A Two-Front War : Targeting Synchronous Metastatic Pancreatic and Renal Cell Carcinomas with the Combination of Gemcitabine and Sunitinib

“…Although pancreatic and kidney cancers are known to be independent, a crucial step in the diagnosis process of synchronous MPT is to eliminate a possible connection between the two different tumors [5]. Interesting genetic analysis of patients with concomitant pancreatic and renal cancers demonstrated microsatellite instability and mutations of codon 12 of k-ras gene [6,7]. Overall, the management plan of synchronous tumors is dictated by the staging of each primary tumor.…”

Pancreatic resection in patients with synchronous extra‐pancreatic malignancy: outcomes and complications

“…Epidemiological studies suggest a rising incidence of multiple primary malignancies in recent years, largely attributable to increased lifespan and cancer survivorship . Research into patients with PDAC and concurrent extra‐pancreatic malignancies outside the scope of hereditary cancer syndromes is limited and is reported most frequently in the form of case reports . In this study, we aimed to evaluate our experience with patients diagnosed with synchronous pancreatic and extra‐pancreatic malignancies who underwent pancreatic resections.…”